The mutational landscape of prostate cancer.
暂无分享,去创建一个
Jun Luo | Henrik Grönberg | Tapio Visakorpi | Mark A Rubin | Christopher E Barbieri | James W F Catto | M. Rubin | H. Grönberg | T. Visakorpi | Jun Luo | J. Catto | C. Barbieri | A. Bjartell | C. Bangma | Z. Culig | Anders Bjartell | Chris H Bangma | Zoran Culig
[1] Jindan Yu,et al. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. , 2013, Cancer research.
[2] M. Rubin,et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. , 2013, European urology.
[3] G. Sauter,et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. , 2013, Cancer research.
[4] Johan Lindberg,et al. The mitochondrial and autosomal mutation landscapes of prostate cancer. , 2013, European urology.
[5] A. Sivachenko,et al. Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.
[6] John T. Wei,et al. Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study , 2013, Clinical Cancer Research.
[7] U. Stenman,et al. A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells , 2013, Prostate Cancer and Prostatic Diseases.
[8] V. Beneš,et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. , 2013, Cancer cell.
[9] J. Lindberg,et al. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. , 2013, European urology.
[10] G. Sauter,et al. Marked heterogeneity of ERG expression in large primary prostate cancers , 2013, Modern Pathology.
[11] M. Loda,et al. EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent , 2012, Science.
[12] F. Brimo,et al. PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity , 2012, BMC Cancer.
[13] R. Eeles,et al. The role of genetic markers in the management of prostate cancer. , 2012, European urology.
[14] Tapio Visakorpi,et al. Androgen receptor (AR) aberrations in castration-resistant prostate cancer , 2012, Molecular and Cellular Endocrinology.
[15] J. Lindberg,et al. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer , 2012, Oncogene.
[16] C. Plass,et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. , 2012, The American journal of pathology.
[17] P. Nelson,et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. , 2012, Cancer research.
[18] A. Sivachenko,et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.
[19] Benjamin J. Raphael,et al. The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .
[20] R. Lothe,et al. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer , 2012, Genes, chromosomes & cancer.
[21] T. Visakorpi,et al. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer , 2012, Oncogene.
[22] Wei Li,et al. Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. , 2011, Cancer research.
[23] S. Clark,et al. Epigenetics in prostate cancer: biologic and clinical relevance. , 2011, European urology.
[24] Stephen J. Salipante,et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers , 2011, Proceedings of the National Academy of Sciences.
[25] K. Pantel,et al. The anti‐interleukin‐6 antibody siltuximab down‐regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study , 2011, The Prostate.
[26] Martha E. Zeeman,et al. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. , 2011, Cancer cell.
[27] K. Knudsen,et al. Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer , 2011, Nature Reviews Urology.
[28] S. Dhanasekaran,et al. Characterization of KRAS rearrangements in metastatic prostate cancer. , 2011, Cancer discovery.
[29] Wei Yan,et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. , 2011, Cancer cell.
[30] Sarat Chandarlapaty,et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. , 2011, Cancer cell.
[31] Antonio Alcaraz,et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. , 2011, European urology.
[32] S. Varambally,et al. Therapeutic Targeting of SPINK1-Positive Prostate Cancer , 2011, Science Translational Medicine.
[33] Eric S. Lander,et al. The genomic complexity of primary human prostate cancer , 2010, Nature.
[34] M. Rubin,et al. Testing mutual exclusivity of ETS rearranged prostate cancer , 2010, Laboratory Investigation.
[35] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[36] Martin J. Aryee,et al. Androgen-induced TOP2B mediated double strand breaks and prostate cancer gene rearrangements , 2010, Nature Genetics.
[37] Francesca Demichelis,et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma , 2010, Nature Medicine.
[38] C. Cooper,et al. Studies of TMPRSS2-ERG Gene Fusions in Diagnostic Trans-Rectal Prostate Biopsies , 2010, Clinical Cancer Research.
[39] W. Gerald,et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer , 2010, British Journal of Cancer.
[40] L. Kenner,et al. Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. , 2009, Cancer research.
[41] M. Rubin,et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. , 2009, European urology.
[42] H. Klocker,et al. Genetic alterations in the PI3K pathway in prostate cancer. , 2009, Anticancer research.
[43] C. Sander,et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis , 2009, Nature Genetics.
[44] Pier Paolo Pandolfi,et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.
[45] D. Dearnaley,et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. , 2009, Cancer research.
[46] M. Gerstein,et al. Distinct genomic aberrations associated with ERG rearranged prostate cancer , 2009, Genes, chromosomes & cancer.
[47] Dietmar Fuchs,et al. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. , 2008, Endocrine-related cancer.
[48] R. Vessella,et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.
[49] John T. Wei,et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. , 2008, Cancer cell.
[50] T. Golub,et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. , 2008, Journal of the National Cancer Institute.
[51] P. Nelson,et al. A causal role for ERG in neoplastic transformation of prostate epithelium , 2008, Proceedings of the National Academy of Sciences.
[52] U. Stenman,et al. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. , 2007, European urology.
[53] J. Brooks,et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. , 2007, Cancer research.
[54] S. Dhanasekaran,et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.
[55] Y Pawitan,et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.
[56] T. Tammela,et al. MicroRNA expression profiling in prostate cancer. , 2007, Cancer research.
[57] John T. Wei,et al. Integrative molecular concept modeling of prostate cancer progression , 2007, Nature Genetics.
[58] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[59] T. Visakorpi,et al. Alterations of androgen receptor in prostate cancer , 2004, The Journal of Steroid Biochemistry and Molecular Biology.
[60] R. Tibshirani,et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[61] P. Pandolfi,et al. Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.
[62] E. Bissonette,et al. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. , 2003, Cancer research.
[63] S. Dhanasekaran,et al. The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.
[64] M. Loda,et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. , 1999, Cancer research.
[65] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[66] J. Herman,et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers , 1998, Oncogene.
[67] J. Herman,et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. , 1997, Cancer research.
[68] J Isola,et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. , 1997, Cancer research.
[69] Jorma Isola,et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.